Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 218 citing articles:

Anti-obesity drug discovery: advances and challenges
Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, et al.
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 3, pp. 201-223
Open Access | Times Cited: 683
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 6, pp. 514-526
Closed Access | Times Cited: 459
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Ildiko Lingvay, Priya Sumithran, Ricardo V. Cohen, et al.
The Lancet (2021) Vol. 399, Iss. 10322, pp. 394-405
Closed Access | Times Cited: 365
GLP-1 physiology informs the pharmacotherapy of obesity
Daniel J. Drucker
Molecular Metabolism (2021) Vol. 57, pp. 101351-101351
Open Access | Times Cited: 273
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
John R. Ussher, Daniel J. Drucker
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 463-474
Closed Access | Times Cited: 211
Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial
Ornella Verrastro, Simona Panunzi, Lidia Castagneto‐Gissey, et al.
The Lancet (2023) Vol. 401, Iss. 10390, pp. 1786-1797
Open Access | Times Cited: 174
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Michael A. Nauck, David A. D‘Alessio
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 173
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
David C.W. Lau, Lars Erichsen, Ann Marie Ocampo Francisco, et al.
The Lancet (2021) Vol. 398, Iss. 10317, pp. 2160-2172
Open Access | Times Cited: 135
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Juan P. Frías, Srikanth Deenadayalan, Lars Erichsen, et al.
The Lancet (2023) Vol. 402, Iss. 10403, pp. 720-730
Closed Access | Times Cited: 135
Semaglutide for the treatment of overweight and obesity: A review
Natasha C. Bergmann, Melanie J. Davies, Ildiko Lingvay, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 18-35
Open Access | Times Cited: 106
Breakthroughs in therapies for NASH and remaining challenges
Vlad Ratziu, Sven Francque, Arun J. Sanyal
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1263-1278
Open Access | Times Cited: 104
What is the pipeline for future medications for obesity?
Eka Melson, Uzma Ashraf, Dimitris Papamargaritis, et al.
International Journal of Obesity (2024)
Open Access | Times Cited: 103
Pharmacotherapy of type 2 diabetes: An update and future directions
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, et al.
Metabolism (2022) Vol. 137, pp. 155332-155332
Closed Access | Times Cited: 93
New insights into the treatment of obesity
Matthias Blüher, Mohini Aras, Louis J. Aronne, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 8, pp. 2058-2072
Closed Access | Times Cited: 85
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Ania M. Jastreboff, Robert F. Kushner
Annual Review of Medicine (2023) Vol. 74, Iss. 1, pp. 125-139
Open Access | Times Cited: 78
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Daniel J. Drucker
Diabetes Care (2024)
Open Access | Times Cited: 72
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Julian M. Yabut, Daniel J. Drucker
Endocrine Reviews (2022) Vol. 44, Iss. 1, pp. 14-32
Open Access | Times Cited: 70
An update on peptide-based therapies for type 2 diabetes and obesity
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2023) Vol. 161, pp. 170939-170939
Open Access | Times Cited: 70
Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review
Manoj K. Mahapatra, Muthukumar Karuppasamy, Biswa Mohan Sahoo
Pharmaceutical Research (2022) Vol. 39, Iss. 6, pp. 1233-1248
Open Access | Times Cited: 69
Derivatization with fatty acids in peptide and protein drug discovery
Peter Kurtzhals, Søren Østergaard, Erica Nishimura, et al.
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 1, pp. 59-80
Closed Access | Times Cited: 69
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Rachel Sinha, Dimitris Papamargaritis, Jack A. Sargeant, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 1, pp. 25-45
Open Access | Times Cited: 59
GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications
Jonathan E. Campbell, Timo D. Müller, Brian Finan, et al.
Cell Metabolism (2023) Vol. 35, Iss. 9, pp. 1519-1529
Open Access | Times Cited: 56
The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities
Thomas A. Wadden, Ariana M. Chao, Molly Moore, et al.
Current Obesity Reports (2023) Vol. 12, Iss. 4, pp. 453-473
Open Access | Times Cited: 54
Obesity and cardiovascular disease: an ESC clinical consensus statement
Konstantinos C. Koskinas, Emeline M. Van Craenenbroeck, Charalambos Antoniades, et al.
European Heart Journal (2024)
Open Access | Times Cited: 41
Medications for Obesity
Kimberly A. Gudzune, Robert F. Kushner
JAMA (2024) Vol. 332, Iss. 7, pp. 571-571
Closed Access | Times Cited: 40
Page 1 - Next Page

Scroll to top